Morris M E, Yuen V, Tang B K, Pang K S
Faculty of Pharmacy, University of Toronto, Ontario, Canada.
J Pharmacol Exp Ther. 1988 May;245(2):614-24.
Sulfation and glucuronidation are two parallel pathways for the metabolism of phenolic substrates. Gentisamide (GAM) was used as a model compound to examine the effects of parallel competing pathways on drug disappearance and metabolite formation in the once-through perfused rat liver preparation. GAM was found to form one glucuronide (GAM-5G) and two sulfate (GAM-2S and GAM-5S) conjugates. These GAM conjugates were biosynthesized in recirculating rat liver preparations, and were isolated by preparative high-performance liquid chromatography. Specific incorporation of 35S-sodium sulfate and [14C]glucose into GAM sulfate and glucuronide conjugates revealed corresponding elution patterns as labeled GAM metabolites. Their identities were characterized by enzymatic and acid hydrolyses and by NMR spectroscopy. Gentisamide-5-sulfate (GAM-5S) and gentisamide-5-glucuronide (GAM-5G) are major metabolites, and gentisamide-2-sulfate (GAM-2S) is a minor metabolite. Single-pass rat liver perfusions were used to examine the effect of stepwise increases/decreases of input GAM concentration (CIn) on the extraction ratio (E) of GAM and formation of metabolites. The E of GAM remained constant (about 0.89) at input concentrations from 0.9 to 120 microM and decreased at CIn greater than 120 microM. Metabolite patterns, however, changed with GAM CIn, even when E was constant at CIn up to 120 microM. GAM-5S was present as the major metabolite of GAM at all GAM CInS in most liver preparations but the proportions of GAM-5S and GAM-2S decreased at increasing CIn; the proportion of GAM-5G, a minor metabolite at low CIn, increased with increasing CIn. Biliary excretion rates at steady state accounted for 5.3 +/- 2.7% (mean +/- S.D.) of the input rate: GAM-5G was the predominant metabolite found. Fitting the metabolic data (sum of the rates of efflux in bile and perfusate at steady state) and the logarithmic average drug concentration at the various CIn to the Michaelis-Menten equation furnished parameter estimates for the three metabolic pathways. The estimated Km and Vmax values were quite comparable: for GAM-2S formation, 22 microM and 287 nmol/min; for GAM-5S formation, 26 microM and 978 nmol/min; for GAM-5G formation, 71 microM and 1062 nmol/min, indicating that sulfation and glucuronidation are effective competing pathways of each other. In viewing the fate of GAM over the CIn range, a changing metabolic fate of GAM over a constant E was noted at CIn less than 120 microM: the sum of the rates of metabolite formation was proportional to CIn.(ABSTRACT TRUNCATED AT 400 WORDS)
硫酸化和葡萄糖醛酸化是酚类底物代谢的两条平行途径。龙胆酰胺(GAM)被用作模型化合物,以研究在一次性灌注大鼠肝脏制剂中平行竞争途径对药物消除和代谢物形成的影响。发现GAM可形成一种葡萄糖醛酸苷(GAM-5G)和两种硫酸酯(GAM-2S和GAM-5S)共轭物。这些GAM共轭物在大鼠肝脏再循环制剂中生物合成,并通过制备型高效液相色谱法分离。将35S-硫酸钠和[14C]葡萄糖特异性掺入GAM硫酸酯和葡萄糖醛酸苷共轭物中,显示出与标记的GAM代谢物相对应的洗脱模式。它们的结构通过酶促水解、酸水解和核磁共振光谱进行表征。龙胆酰胺-5-硫酸酯(GAM-5S)和龙胆酰胺-5-葡萄糖醛酸苷(GAM-5G)是主要代谢物,而龙胆酰胺-2-硫酸酯(GAM-2S)是次要代谢物。采用单通道大鼠肝脏灌注法,研究逐步增加/降低输入GAM浓度(CIn)对GAM提取率(E)和代谢物形成的影响。在输入浓度为0.9至120μM时,GAM的E保持恒定(约0.89),而在CIn大于120μM时降低。然而,即使在CIn高达120μM时E保持恒定,代谢物模式也会随GAM CIn而变化。在大多数肝脏制剂中,在所有GAM CIn下,GAM-5S都是GAM的主要代谢物,但随着CIn增加,GAM-5S和GAM-2S的比例降低;GAM-5G在低CIn时是次要代谢物,其比例随CIn增加而增加。稳态胆汁排泄率占输入率的5.3±2.7%(平均值±标准差):GAM-5G是主要发现的代谢物。将代谢数据(稳态时胆汁和灌注液中流出率之和)和不同CIn下的对数平均药物浓度拟合到米氏方程中,得到了三种代谢途径的参数估计值。估计的Km和Vmax值相当可比:对于GAM-2S形成,分别为22μM和287nmol/min;对于GAM-5S形成,分别为26μM和978nmol/min;对于GAM-5G形成,分别为71μM和1062nmol/min,表明硫酸化和葡萄糖醛酸化是彼此有效的竞争途径。在观察CIn范围内GAM的命运时,发现在CIn小于120μM时,在恒定E下GAM的代谢命运发生变化:代谢物形成速率之和与CIn成正比。(摘要截断于400字)